Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

880 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
Amoroso L, Castel V, Bisogno G, Casanova M, Marquez-Vega C, Chisholm JC, Doz F, Moreno L, Ruggiero A, Gerber NU, Fagioli F, Hingorani P, Melcón SG, Slepetis R, Chen N, le Bruchec Y, Simcock M, Vassal G. Amoroso L, et al. Among authors: ruggiero a. Eur J Cancer. 2020 Aug;135:89-97. doi: 10.1016/j.ejca.2020.04.031. Epub 2020 Jun 15. Eur J Cancer. 2020. PMID: 32554315 Clinical Trial.
High response rate to cisplatin/etoposide regimen in childhood low-grade glioma.
Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, Riva D, Ruggiero A, Valentini L, Mazza E, Genitori L, Di Rocco C, Navarria P, Casanova M, Ferrari A, Luksch R, Terenziani M, Balestrini MR, Colosimo C, Fossati-Bellani F. Massimino M, et al. Among authors: ruggiero a. J Clin Oncol. 2002 Oct 15;20(20):4209-16. doi: 10.1200/JCO.2002.08.087. J Clin Oncol. 2002. PMID: 12377964 Clinical Trial.
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.
Cefalo G, Massimino M, Ruggiero A, Barone G, Ridola V, Spreafico F, Potepan P, Abate ME, Mascarin M, Garrè ML, Perilongo G, Madon E, Colosimo C, Riccardi R. Cefalo G, et al. Among authors: ruggiero a. Neuro Oncol. 2014 May;16(5):748-53. doi: 10.1093/neuonc/not320. Epub 2014 Jan 30. Neuro Oncol. 2014. PMID: 24482446 Free PMC article. Clinical Trial.
Salvage rates and prognostic factors after relapse in children and adolescents with malignant peripheral nerve sheath tumors.
Bergamaschi L, Bisogno G, Manzitti C, D'Angelo P, Milano GM, Scagnellato A, Cappelletti M, Chiaravalli S, Dall'Igna P, Alaggio R, Ruggiero A, Di Martino M, Affinita MC, Pierobon M, Garaventa A, Casanova M, Ferrari A. Bergamaschi L, et al. Among authors: ruggiero a. Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26816. Epub 2017 Sep 19. Pediatr Blood Cancer. 2018. PMID: 28926683 Clinical Trial.
Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma in children: Report from the AIEOP Soft Tissue Sarcoma Committee.
Compostella A, Affinita MC, Casanova M, Milano GM, Scagnellato A, Dall'Igna P, Chiaravalli S, Pierobon M, Manzitti C, Zanetti I, Schiavetti A, Sorbara S, Mura RM, Ruggiero A, Ferrari A, Bisogno G. Compostella A, et al. Among authors: ruggiero a. Tumori. 2019 Apr;105(2):138-143. doi: 10.1177/0300891618792479. Epub 2018 Aug 22. Tumori. 2019. PMID: 30131003
Prognostic role of pleural effusion or ascites in localized rhabdomyosarcoma.
Di Carlo D, Ferrari A, Toffolutti T, Milano GM, Manzitti C, Ruggiero A, Dall'Igna P, Melchionda F, Zanetti I, Scarzello G, Bisogno G. Di Carlo D, et al. Among authors: ruggiero a. Pediatr Blood Cancer. 2019 Nov;66(11):e27932. doi: 10.1002/pbc.27932. Epub 2019 Aug 5. Pediatr Blood Cancer. 2019. PMID: 31385434
880 results